Transdermal and dermal drug delivery is problematic because the skin, as a natural barrier, has a very low permeation rate. Therefore several methods have been assessed to increase this rate locally and temporarily. One approach is the use of vesicle formulations. In this paper the effectiveness of conventional and deformable vesicles as drug delivery systems as well as their possible mode of action as permeation enhancers or transdermal drug carriers will be discussed.:
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ddtec.2005.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exposure experiments and machine learning revealed that personal care products can significantly increase transdermal exposure of SVOCs from the environment.
J Hazard Mater
January 2025
Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), School of Environmental Science and Technology, Dalian University of Technology, Dalian 116024, China.
We investigated the impacts of personal care products (PCPs) on dermal exposure to semi-volatile organic compounds (SVOCs), including phthalates, organophosphate esters, polycyclic aromatic hydrocarbons (PAHs), ultraviolet filters, and p-phenylenediamines, through an experiment from volunteers, explored the impact mechanisms of PCP ingredients on dermal exposure, and predicted the PCP effects on SVOC concentrations in human serum using machine learning. After applying PCPs, namely lotion, baby oil, sunscreen, and blemish balm, the dermal adsorption of SVOCs increased significantly by 1.63 ± 0.
View Article and Find Full Text PDFTopical Carboxytherapy for Skin Rejuvenation.
J Clin Aesthet Dermatol
January 2025
Drs. Simmons-O'Brien and Orlinsky are with Simmons-O'Brien & Orlinsky, LLC, in Towson, Maryland.
Driven by public demand, new safe and effective approaches for achieving dermal rejuvenation are continuously being developed. Recently, there has been growing interest and advances in carbon dioxide therapy, or carboxytherapy. Based on the Bohr effect, carboxytherapy enhances the release of O from the blood into the surrounding tissues in response to increased blood CO.
View Article and Find Full Text PDF[Cutaneous ulceration in dermatomyositis : Case reports with positive anti-NXP-2/anti-TIF1-gamma antibody status].
Dermatologie (Heidelb)
January 2025
Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Leipzig, Philipp-Rosenthal-Str. 23, 04103, Leipzig, Deutschland.
Painful ulcerations developed in a 33-year-old woman with anti-NXP-2-positive dermatomyositis in the facial and trunk areas and a 67-year-old woman with TIF1-gamma-positive dermatomyositis on the hands, while undergoing systemic therapy with azathioprine or low-dose methylprednisolone and cyclic administration of intravenous immunoglobulins (IVIG), respectively. In the laboratory workup, the anti-MDA‑5 antibody status remained negative and the creatine kinase (CK) normal in both patients, while histopathological examinations were nonspecific. Intensive topical class 4 corticosteroid therapy and continuation of the immunosuppressive or immunomodulating therapy led to healing of the ulcerative skin lesions.
View Article and Find Full Text PDFPatches containing quercetin microcapsules to ameliorate dermal herpes simplex virus injuries in mice.
Eur J Pharm Biopharm
February 2025
Department of Chemistry, State University of Londrina, Londrina, PR, Brazil; Department of Pharmaceutical Sciences, State University of Londrina, Londrina, PR, Brazil. Electronic address:
This study aimed to develop patches containing quercetin-loaded microcapsules and to evaluate their in vitro and in vivo safety and efficacy in preclinical surveys. A set of in vitro experiments evidenced the virucidal activity of quercetin against the HSV-1-KOS (sensitive to acyclovir) and HSV-1-AR (resistant to acyclovir) strains, with improved outcomes upon the first. The patches presented a homogeneous aspect, were easily handled, had a suitable bioadhesion, and possessed mechanical properties of soft and weak material, besides a pH compatible with human skin.
View Article and Find Full Text PDFA human skin-on-a-chip platform for microneedling-driven skin cancer treatment.
Mater Today Bio
February 2025
Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90024, USA.
Skin-on-a-chip models provide physiologically relevant platforms for studying diseases and drug evaluation, replicating the native skin structures and functions more accurately than traditional 2D or simple 3D cultures. However, challenges remain in creating models suitable for microneedling applications and monitoring, as well as developing skin cancer models for analysis and targeted therapy. Here, we developed a human skin/skin cancer-on-a-chip platform within a microfluidic device using bioprinting/bioengineering techniques.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!